98%
921
2 minutes
20
Background: The predictive value of the triglyceride-glucose (TyG) index in patients with obstructive sleep apnea (OSA) remains unclear. Therefore, we aimed to investigate the associations between the TyG index and all-cause and non-cardiovascular (non-CV) mortality in an OSA cohort, focusing on age differences.
Methods: This study enrolled 10,274 patients with OSA from the National Health and Nutrition Examination Survey (2005-2008 and 2015-2018). Mortality outcomes were ascertained by linking to National Death Index records through December 31, 2019. Multivariate Cox proportional hazards regression models with restricted cubic splines and interaction tests with age were employed to evaluate the association between the TyG index and all-cause and non-CV mortality. Kaplan-Meier analysis was used to evaluate mortality differences.
Results: During a mean follow-up of 88 months, 1027 all-cause deaths occurred, of which non-CV deaths accounted for 77.8% of the total mortality burden. After fully adjusting for potential confounders, our study explored a U-shaped association between the TyG index and all-cause/non-CV mortality (both non-linear p < 0.001), with inflection points at 9.27 and 9.2. Age yielded a statistically significant interaction between the TyG index and mortality. The TyG index was linearly associated with higher risks of all-cause [Hazard Ratio (HR) 1.30, 95% Confidence Interval (CI): 1.09-1.55, p = 0.004] and non-CV mortality (HR 1.33, 95% CI: 1.08-1.62, p = 0.006) in participants aged < 65, but not in participants age ≥ 65. Kaplan-Meier curves indicated that the patients with the higher TyG index had a significantly lower survival probability (All-cause mortality: p for log-rank test < 0.001; non-CV mortality: p for log-rank test = 0.001).
Conclusions: This study identified a U-shaped association between the TyG index and all-cause and non-CV mortality in an OSA population, with a statistically significant interaction with age. A linear relationship was detected between the TyG index and mortality in those aged < 65, while a non-linear association was established in those aged ≥ 65.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12219928 | PMC |
http://dx.doi.org/10.1186/s13098-025-01791-9 | DOI Listing |
Am J Cardiovasc Drugs
September 2025
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, K1927C, Queen Mary Hospital, 102 Pokfulam Road, Pok Fu Lam, Hong Kong SAR, China.
Background: Colchicine has been incorporated into major clinical guidelines for the secondary prevention of cardiovascular disease (CVD). However, recent randomized trials have presented contradictory results.
Objective: We aimed to synthesize the current evidence on colchicine in secondary CVD protection, using a cumulative-dose approach.
Nutr Metab Cardiovasc Dis
July 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Cardiology, The Sakakibara Heart Institute of Okayama, Okayama, Japan.
Background And Aims: Upper limb muscle thickness assessed by ultrasound could be useful to estimate whole body muscle mass. We investigated the association between low upper limb muscle thickness and prognosis in older patients with heart failure (HF).
Methods And Results: This study was a post-hoc analysis of a prospective multicenter cohort, namely, the SONIC-HF study.
Heart Rhythm
August 2025
Department of Cardiology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China. Electronic address:
Background: Left atrial appendage closure (LAAC) is primarily indicated for stroke prevention in patients with atrial fibrillation (AF) who have contraindications to long-term oral anticoagulants (OACs). However, the long-term comparative benefits of LAAC vs OACs in the broader AF population remain unclear.
Objective: To study aimed to assess the long-term efficacy and safety of LAAC compared with OACs in patients with AF, we conducted a meta-analysis of randomized controlled trials (RCTs).
J Nephrol
July 2025
Department of Internal Medicine, Yonsei University College of Medicine, Institute of Kidney Disease Research, Yonsei-ro 50, Seodaemun-gu, Seoul, Republic of Korea.
Background: Physical activity is important for health and longevity, but little is known on patients living with chronic kidney disease (CKD). In fact, most studies in patients with CKD have relied on self-reported data, highlighting an unmet need for studies using objective measurements. We investigated the association between device-measured physical activity and adverse outcomes by CKD status.
View Article and Find Full Text PDFJ Diabetes
July 2025
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Objective: This study aimed to explore the association between plasma big endothelin-1 (ET-1) and major adverse cardiovascular events (MACE) in CAD patients who underwent PCI with a focus on the influence of kidney function and diabetes status in secondary prevention.
Methods: A prospective cohort of CAD patients underwent PCI and patients with impaired kidney function and diabetes were initially screened and categorized separately, subdivided based on ET-1 levels. The primary outcome was MACE, including all-cause mortality, nonfatal myocardial infarction, unplanned revascularization, and stroke.